News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Study: Degludec Cuts Night-Time Hypoglycemia Risk


10/3/2012 7:55:48 AM

A new study shows that insulin degludec, an investigational diabetes drug developed by the world's largest insulin maker, Novo Nordisk A/S (NOVO-B.KO), sharply cuts diabetes patients' risk of incurring night-time hypoglycaemia compared with traditional insulin, the company said Tuesday. Compared with insulin glargine, patients had a 43% lower rate of night-time hypoglycaemia, according to the two-year study, which investigated 1,030 patients with type 2 diabetes. The patients, who hadn't previously been treated with insulin, also had a significantly lower rate of severe hypoglycaemia, according to the data, which were presented at the Annual Meeting of the European Association for the Study of Diabetes in Berlin.

Read at Fox News


comments powered by Disqus
Fox News
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES